ClinicalTrials.gg
CompletedNCT05108623Updated Apr 24, 2024

A Study Investigating agenT-797 in Participants With Relapsed/Refractory Solid Tumors

A Phase 1 interventional study of agenT-797 and Approved ICIs in Tumor, Solid, sponsored by MiNK Therapeutics. Completed at 8 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-24.

Sponsored by MiNK Therapeutics (formerly part of Agenus Inc.) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jan 2024, 2 years 10 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
34
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a Phase 1, open-label study to explore the safety, tolerability, and preliminary clinical activity of agenT-797, an unmodified, allogeneic iNKT cell therapy, in participants with relapsed/refractory (r/r) solid tumors, as well as define the recommended phase II dose in solid tumors. This Phase 1 study will also explore the safety, tolerability, and preliminary clinical activity of agenT-797 in combination with approved immune checkpoint inhibitors (ICIs), including pembrolizumab and nivolumab, in participants with r/r solid tumors.

02

Conditions studied

  • Tumor, Solid

Browse trials for

Keywords

  • Tumor
  • Solid Tumor
  • Immunotherapy
  • iNKT cells
03

In context

Neoplasms

10,832 studies on the registry are indexed under Neoplasms; 2,324 are open to participants now.

This study's enrollment of 34 is below the median of 60 across 7,712 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

MiNK Therapeutics is the lead sponsor of 4 studies on the registry; 1 is open to participants now.

First submitted before MiNK Therapeutics left Agenus Inc..

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histological or cytological evidence of solid tumor for which no standard therapy is available or standard therapy has failed
  • per 1.1 as assessed by local site Investigator/radiology. Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions
  • Part 2 only, participants must have progressed per Investigator assessment on pembrolizumab or nivolumab, and agree and are able to continue on the inhibitor(s) while on study
  • No other medical, surgical, or psychiatric condition (including active substance abuse) that would interfere with compliance to the protocol, as determined by the Principal Investigator

Exclusion criteria

Exclusion Criteria:

  • Concurrent invasive
  • Brain and/or that are untreated or require current therapy
  • Prior radiotherapy within 2 weeks of start of study treatment
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
34 participants (actual)

Study arms

  • Experimental
    Part 1: Monotherapy with agenT-797

    3+3 Dose escalation of agenT-797 will be administered as a single intravenous (IV) infusion.

    Drug: agenT-797

  • Experimental
    Part 2: agenT-797 in Combination with approved ICIs

    Single prespecified dose of agenT-797 administered by IV infusion in combination with approved ICIs administered in accordance with manufacturer instructions and institutional guidelines as per standard of care

    Drug: agenT-797 · Drug: Approved ICIs

Interventions

  • agenT-797 is an off-the-shelf cell therapy consisting of ≥ 95% allogeneic human unmodified iNKT cells isolated from 1 healthy donor mononuclear cell apheresis unit and expanded ex vivo.

  • DrugApproved ICIs

    Nivolumab and pembrolizumab

This study also gives Pembrolizumab, Nivolumab. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Number Of Participants With Treatment-emergent Adverse Events (TEAEs)

    This will be determined according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 (NCI CTCAE v5.0).

    Time frame: Baseline through 12 months

  2. Number Of Adverse Events (AEs) By The Dose Of iNKT Cell Therapy

    This will be determined according to the NCI CTCAE v5.0.

    Time frame: Baseline through 12 months

  3. Number Of TEAEs By The Dose Of iNKT Cell Therapy

    This will be determined according to the NCI CTCAE v5.0.

    Time frame: Baseline through 12 months

  4. Severity Grade Of AEs By Dose Of iNKT Cell Therapy

    This will be determined according to the NCI CTCAE v5.0.

    Time frame: Baseline through 12 months

  5. Number Of Dose-limiting Toxicities

    Time frame: Baseline through first 14 days after administration

Secondary outcomes

  1. Persistence Of agenT-797 In Peripheral Blood Samples

    This will be measured as a length of time, through collection of peripheral blood mononuclear cells and analysis by flow cytometry.

    Time frame: Baseline/Day 1 (pre-infusion, 5 minutes, 0.25, 0.5, 1, 2, and 4 hours after cell infusion), and on Days 2, 5, 8, 15, 22, and 29; Weeks 6, 8, and 12; and Months 6, 9, and 12

  2. Objective Response Rate (ORR)

    For solid tumors, this will be determined per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 guidelines and for prostate cancer (not evaluable per RECIST 1.1), Prostate Cancer Working Group 3 (PCWG3) will be used.

    Time frame: Up to 12 months

  3. Duration Of Response (DOR)

    For solid tumors, this will be determined per RECIST 1.1 guidelines and for prostate cancer (not evaluable per RECIST 1.1), PCWG3 will be used.

    Time frame: Up to 12 months

  4. Progression-free Survival (PFS)

    For solid tumors, this will be determined per RECIST 1.1 guidelines and for prostate cancer (not evaluable per RECIST 1.1), PCWG3 will be used.

    Time frame: Up to 12 months

  5. Incidence Of Panel-reactive Antibody

    Time frame: Baseline/Day 1 (pre-infusion), Day 8, Day 15, Day 29, Week 8, Week 12, Month 6, and end of study visit (up to 12 months)

  6. Incidence Of Donor-specific Antibody

    Time frame: Baseline/Day 1 (pre-infusion), Day 8, Day 15, Day 29, Week 8, Week 12, Month 6, and end of study visit (up to 12 months)

07

Study locations

8 sites
  • University of Southern California
    Los Angeles, California 90033, United States
  • University of Colorado
    Aurora, Colorado 80045, United States
  • Norton Cancer Health
    Louisville, Kentucky 40241, United States
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215, United States
  • University of Cincinnati Cancer Center
    Cincinnati, Ohio 45267, United States
  • Providence Portland Medical Center
    Portland, Oregon 97213, United States
  • LifeSpan - Rhode Island Hospital
    Providence, Rhode Island 02903, United States
  • Sarah Cannon Research Institute
    Nashville, Tennessee 37203, United States
08

References and documents

Publications

  • Hadfield MJ, Safran H, Purbhoo MA, Grossman JE, Buell JS, Carneiro BA. Overcoming resistance to programmed cell death protein 1 (PD-1) blockade with allogeneic invariant natural killer T-cells (iNKT). Oncogene. 2024 Mar;43(10):758-762. doi: 10.1038/s41388-024-02948-y. Epub 2024 Jan 29. PubMed 38281989 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2022 to primary completion in Jan 2024, 23 months.

Of 676 industry-sponsored phase 1 interventional studies under Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 61. This study's 23 months is below that.

Counting every sponsor, half of 903 studies reached it within 40 months; a quarter within 23 and three quarters within 64.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 12, 2021
First posted
Nov 5, 2021
StartActual
Jan 28, 2022
Primary completionActual
Jan 2, 2024
CompletionActual
Jan 2, 2024
Last update
Apr 24, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 24, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05108623
Lead sponsor
MiNK Therapeutics
Responsible party
Sponsor
First posted
Nov 5, 2021
Start date
Jan 28, 2022
Primary completion
Jan 2, 2024
Completion
Jan 2, 2024
Last update
Apr 24, 2024

Study contacts

Medical Director
study director · MiNK Therapeutics

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Allogeneic Invariant Natural Killer T-cells agenT-797

Start the discussion